var data={"title":"Antithymocyte globulin (equine, Atgam): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Antithymocyte globulin (equine, Atgam): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6490?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=antithymocyte-globulin-equine-atgam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Antithymocyte globulin (equine, Atgam): Patient drug information&quot;</a> and <a href=\"topic.htm?path=antithymocyte-globulin-equine-atgam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Antithymocyte globulin (equine, Atgam): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708631\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Anaphylaxis</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antithymocyte globulins can cause anaphylaxis when injected intravenously. Although antithymocyte globulin (equine) is processed to reduce the level of antibodies that will react to non-T cells, health care providers should be prepared for the potential risk of anaphylaxis and monitor patients for signs and symptoms during infusion.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190616\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Atgam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190617\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Atgam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190635\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Immune Globulin;</li>\n      <li>\n        Immunosuppressant Agent;</li>\n      <li>\n        Polyclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190618\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Test dose: While a skin test is recommended prior to administration of the initial dose, anaphylaxis may still occur in patients who display negative skin tests. Consider testing initially with an epicutaneous prick of undiluted antithymocyte globulin (ATG); if no wheal in 10 minutes, then use 0.02 mL intradermally of a 1:1000 dilution of ATG in normal saline along with a separate saline control of 0.02 mL; observe in 10 minutes. A positive skin reaction consists of a wheal with the initial prick test (undiluted) or &ge;3 mm in diameter larger than the saline control with the diluted intradermal test. Alternatively, a 0.1 mL test dose (5 mg/mL concentration) may be administered intradermally along with a separate saline control; erythema larger than 5 mm in diameter (compared to the control) is considered a positive test (Molldrem 2002). A positive skin test is suggestive of an increased risk for systemic allergic reactions with an infusion. If ATG treatment is deemed appropriate following a positive skin test, the first infusion should be administered in a controlled environment with intensive life support immediately available. A systemic reaction precludes further administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Consider premedication with an antihistamine, corticosteroids, and/or an antipyretic. Concomitant immunosuppressants should also be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Aplastic anemia:</b> IV: 10 to 20 mg/kg once daily for 8 to 14 days, then if needed, may administer every other day for 7 more doses for a total of 21 doses in 28 days <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 40 mg/kg once daily for 4 days in combination with cyclosporine (Rosenfeld 1995; Scheinberg 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft-versus-host disease (GVHD) treatment (off-label use):</b> IV: 30 mg/kg every other day for 6 doses (MacMillan 2007) <b>or</b> 15 mg/kg twice daily for 10 doses (MacMillan 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant, induction therapy (off-</b>\n      <b>label use): </b>IV: 5 to 15 mg/kg daily for the first 3 days after transplant (Hachem 2005). Additional data may be necessary to further define the role of antithymocyte globulin (equine) in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic syndromes, refractory, lower-risk disease (off-label use):</b> IV: 40 mg/kg once daily for 4 days; an intradermal test dose was administered prior to treatment (Molldrem 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190629\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=antithymocyte-globulin-equine-atgam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Antithymocyte globulin (equine, Atgam): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Test dose: While a skin test is recommended prior to administration of the initial dose, anaphylaxis may still occur in patients who display negative skin tests. Consider testing initially with an epicutaneous prick of undiluted antithymocyte globulin (ATG); if no wheal in 10 minutes, then use 0.02 mL intradermally of a 1:1000 dilution of ATG in normal saline along with a separate saline control of 0.02 mL; observe in 10 minutes. A positive skin reaction consists of a wheal with the initial prick test (undiluted) or &ge;3 mm in diameter larger than the saline control with the diluted intradermal test. A positive skin test is suggestive of an increased risk for systemic allergic reactions with an infusion. If ATG treatment is deemed appropriate following a positive skin test, the first infusion should be administered in a controlled environment with intensive life support immediately available. A systemic reaction precludes further administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Consider premedication with an antihistamine, corticosteroids, and/or an antipyretic. Concomitant immunosuppressants should also be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Aplastic anemia, moderate to severe when no HLA-matched sibling donor:</b> IV: 10 to 20 mg/kg once daily for 8 to 14 days; then if needed, may administer every other day for 7 more doses for up to a total of 21 doses in 28 days <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing (in combination with cyclosporine):</i> Children &ge;2 years and Adolescents: IV: 40 mg/kg/day once daily for 4 days (Afable 2011; Rosenfeld 1995; Scheinberg 2009; Scheinberg 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft-versus-host disease (GVHD) treatment (off-label use):</b> Children and Adolescents: IV: 30 mg/kg every other day for 6 doses (MacMillan 2007) <b>or</b> 15 mg/kg twice daily for 10 doses (MacMillan 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190619\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Begin at the lower end of dosing ranges.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25663816\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25663817\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26343201\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) to calculate mg/kg dosing for hematopoietic stem cell transplant conditioning regimens (Bubalo 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9885370\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylaxis: Discontinue infusion immediately; administer epinephrine. May require corticosteroids, respiration assistance, and/or other resuscitative measures. Do not resume infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemolysis (severe and unremitting): May require discontinuation of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190599\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atgam: 50 mg/mL (5 mL) [thimerosal free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190586\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190601\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only. Infuse over at least 4 hours through a 0.2 to 1 micron inline filter. Allow solution to reach room temperature prior to infusion. Infusion must be completed with 24 hours of preparation. Administration through a central line is recommended; high flow veins are preferred to reduce phlebitis (infuse into vascular shunt, arterial venous fistula, or high-flow central vein). May cause vein irritation (chemical phlebitis) if administered peripherally (peripheral administration is not recommended).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor closely throughout the infusion for allergic reactions. Appropriate resuscitative equipment should be nearby during administration. May require premedication with an antipyretic, antihistamine, and/or a corticosteroid to prevent reactions. Discontinue infusion for anaphylaxis or respiratory distress. Administer epinephrine, corticosteroids, antihistamines, and/or antipyretics as indicated to manage reactions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to possible infusion-related reactions, it may be preferable to avoid initiating treatment late in the day or on weekends; consider withholding beta-blockers prior to administration to avoid suppressing compensatory responses to anaphylaxis (Scheinberg, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190600\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aplastic anemia:</b> Treatment of moderate-to-severe aplastic anemia in patients not considered suitable candidates for bone marrow transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: The usefulness of antithymocyte globulin (equine) has not been demonstrated in patients with aplastic anemia who are suitable candidates for transplantation, or in aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi syndrome, or in patients with known prior treatment with myelotoxic agents or radiation therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474660\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute graft-versus-host disease (treatment); Lung transplant (induction therapy); Myelodysplastic syndromes, refractory, lower-risk disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190640\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Antithymocyte globulin equine (Atgam) may be confused with antithymocyte globulin rabbit (Thymoglobulin)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atgam may be confused with Ativan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190593\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills, headache  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Dermatological reaction (wheal/flare), pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Bradycardia, cardiac disease, cardiac failure, chest pain, edema, hypertension, hypotension, myocarditis, phlebitis, thrombophlebitis </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Agitation, brain disease (viral), burning sensation (burning of soles and burning of palms), dizziness, encephalitis, generalized ache, lethargy, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis, night sweats</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, stomatitis, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, hepatosplenomegaly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Anaphylaxis, serum sickness </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Viral infection </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (pain, redness, swelling)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain, joint stiffness, myalgia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Periorbital edema </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Renal function test abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea, pleural effusion, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acute renal failure, anaphylactoid reaction, anemia, apnea, confusion, cough, deep vein thrombosis, disorientation, dizziness, eosinophilia, epigastric pain, epistaxis, erythema, flank pain, gastrointestinal hemorrhage, gastrointestinal perforation, granulocytopenia, hemolysis, hemolytic anemia, herpes simplex infection (reactivation), hiccups, hyperglycemia, infection, involuntary body movements, laryngospasm, malaise, muscle rigidity, neutropenia, pancytopenia, paresthesia, pulmonary edema, pure red cell aplasia, renal artery thrombosis, sore mouth, sore throat, tachycardia, thrombosis of vein (iliac), toxic epidermal necrolysis, tremor, vasculitis, viral hepatitis, weakness, wound dehiscence </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190604\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of systemic reaction (eg, anaphylactic reaction) to prior administration of antithymocyte globulin or any other equine gamma globulin preparation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190590\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis:<b> [US Boxed Warning]: Antithymocyte globulins may cause anaphylaxis when injected intravenously. Although antithymocyte globulin (equine) is processed to reduce the level of antibodies that will react to non-T cells, health care providers should be prepared for the potential risk of anaphylaxis and monitor for signs/symptoms during infusion.</b> Hypersensitivity and anaphylactic reactions may occur; discontinue for symptoms of anaphylaxis; immediate treatment (including epinephrine 1 mg/mL) should be available. Systemic reaction (rash, dyspnea, hypotension, tachycardia, or anaphylaxis) precludes further administration of antithymocyte globulin (equine; ATG). Respiratory distress, hypotension, or pain (chest, flank, or back) may indicate an anaphylactoid/anaphylactic reaction. Serious immune-mediated reactions have been reported (rare), including anaphylaxis, infusion reactions, and serum sickness. Skin testing is recommended prior to administration of the initial ATG dose. A positive skin test is suggestive of an increased risk for systemic allergic reactions with an infusion, although anaphylaxis may occur in patients who display negative skin tests. If ATG treatment is deemed appropriate following a positive skin test, the first infusion should be administered in a controlled environment with intensive life support immediately available. Also observe for signs/symptoms of allergic reactions during repeat courses of administration. Skin testing is not predictive for later development of serum sickness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic toxicity: Thrombocytopenia may occur; may require platelets transfusion support. Discontinue if severe and unremitting leukopenia or thrombocytopenia occur in solid organ transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolysis: Clinically significant hemolysis has been reported (rarely). Severe and unremitting hemolysis may require treatment discontinuation. Chest, flank or back pain may indicate hemolysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic function: Abnormal hepatic function tests have been observed in patients with aplastic anemia and other hematologic disorders receiving ATG.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: ATG is an immunosuppressant; monitor closely for signs of infection. An increased incidence of cytomegalovirus (CMV) infection has been reported in studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal function: Abnormal renal function tests have been observed in patients with aplastic anemia and other hematologic disorders receiving ATG.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live viral vaccines may not replicate and antibody response may be reduced if administered during ATG treatment. Patients should not be immunized with attenuated live viral vaccines prior to planned ATG treatment, during, and after treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Administer via central line due to chemical phlebitis that may occur with a peripheral vein. Dose must be administered over at least 4 hours; patient may need to be pretreated with an antipyretic, antihistamine, and/or corticosteroid. Should be administered with concomitant immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Disease transmission: Product of equine and human plasma; may have a risk of transmitting disease, including a theoretical risk of Creutzfeldt-Jakob disease (CJD).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Potency: Product potency and activity may vary from lot to lot.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298763\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218037\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9107&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belatacept: Antithymocyte Globulin (Equine) may enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased.  Management: A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190606\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in some animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21098376\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if antithymocyte globulin (equine) is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190597\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Complete blood count with differential and platelet count, monitor vital signs during administration; monitor for infusion reactions; monitor for signs/symptoms of infection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Solid organ transplant:</i> Absolute CD3 count (cells/&micro;L) monitoring and CD3 based-dosing has been considered in renal and heart transplant recipients. It may be beneficial in certain patient populations but is not routinely recommended or utilized. Dose adjustments have been recommended based on the CD3 count (Krasinska 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190589\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Immunosuppressant involved in the elimination of antigen-reactive T lymphocytes (killer cells) in peripheral blood or alteration in the function of T-lymphocytes, which are involved in humoral immunity and partly in cell-mediated immunity; induces complete or partial hematologic response in aplastic anemia  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190603\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Poor into lymphoid tissues; binds to circulating lymphocytes, granulocytes, platelets, bone marrow cells</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 5.7 &plusmn; 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323348\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (Atgam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (5 mL): $2,392.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038667\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Atgam (AU, BB, BG, CH, ES, GR, HK, IN, KR, MX, MY, NZ, RU, SG, SI, VE, ZA);</li>\n      <li>Lymphoglobuline (TW);</li>\n      <li>Thymogam (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Afable MG 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. <i>Haematologica</i>. 2011;96(9):1269-1275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/21606164/pubmed\" target=\"_blank\" id=\"21606164\">21606164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atgam (lymphocyte immune globulin, antithymocyte globulin [equine]) [prescribing information]. New York, NY: Pfizer Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23575446\"></a>Fenaux P, Ad&egrave;s L. How we treat lower-risk myelodysplastic syndromes. <i>Blood</i>. 2013;121(21):4280-4286. doi: 10.1182/blood-2013-02-453068.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/23575446/pubmed\" target=\"_blank\" id=\"23575446\">23575446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9679818\"></a>Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation. <i>Transplantation</i>. 1998;66(1):29-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/9679818/pubmed\" target=\"_blank\" id=\"9679818\">9679818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16143251\"></a>Hachem RR, Chakinala MM, Yusen RD, et al. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. <i>J Heart Lung Transplant</i>. 2005;24(9):1320-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/16143251/pubmed\" target=\"_blank\" id=\"16143251\">16143251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hardinger KL, Rhee S, Buchanan P, et al, &ldquo;A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10 Year Results,&rdquo; <i>Transplantation</i>, 2008, 86(7):947-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/18852661/pubmed\" target=\"_blank\" id=\"18852661\">18852661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11981432\"></a>Krasinskas AM, Kreisel D, Acker MA, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. <i>Transplantation</i>. 2002;73(8):1339-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/11981432/pubmed\" target=\"_blank\" id=\"11981432\">11981432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17110457\"></a>MacMillan ML, Couriel D, Weisdorf DJ, et al, &ldquo;A Phase 2/3 Multicenter Randomized Clinical Trial of ABX-CBL versus ATG as Secondary Therapy for Steroid-Resistant Acute Graft-Versus-Host-Disease,&rdquo; <i>Blood</i>, 2007, 109(6):2657-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/17110457/pubmed\" target=\"_blank\" id=\"17110457\">17110457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11858189\"></a>MacMillan ML, Weisdorf DJ, Davies SM, et al, &ldquo;Early Antithymocyte Globulin Therapy Improves Survival in Patients With Steroid-Resistant Acute Graft-Versus-Host Disease,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2002, 8(1):40-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/11858189/pubmed\" target=\"_blank\" id=\"11858189\">11858189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molldrem JJ, Caples M, Mavroudis D, et al, &ldquo;Antithymocyte Globulin for Patients With Myelodysplastic Syndrome,&rdquo; <i>Br J Haematol</i>, 1997, 99(3):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/9401087/pubmed\" target=\"_blank\" id=\"9401087\">9401087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12160363\"></a>Molldrem JJ, Leifer E, Bahceci E, et al, &ldquo;Antithymocyte Globulin for Treatment of Bone Marrow Failure Associated With Myelodysplastic Syndromes,&rdquo; <i>Ann Intern Med,</i> 2002, 137(3):156-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/12160363/pubmed\" target=\"_blank\" id=\"12160363\">12160363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld SJ, Kimball J, Vining D, et al, &ldquo;Intensive Immunosuppression With Antithymocyte Globulin and Cyclosporine as Treatment for Severe Acquired Aplastic Anemia,&rdquo; <i>Blood</i>, 1995, 85(11):3058-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/7756640/pubmed\" target=\"_blank\" id=\"7756640\">7756640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. <i>N Engl J Med</i>. 2011;365(5):430-438. doi: 10.1056/NEJMoa1103975.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/21812672/pubmed\" target=\"_blank\" id=\"21812672\">21812672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheinberg P, Young NS. How I treat acquired aplastic anemia. <i>Blood</i>. 2012;120(6):1185-1196. doi: 10.1182/blood-2011-12-274019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/22517900/pubmed\" target=\"_blank\" id=\"22517900\">22517900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. <i>Haematologica</i>. 2009;94(3):348-354.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/19181786/pubmed\" target=\"_blank\" id=\"19181786\">19181786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18413642\"></a>Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. <i>J Clin Oncol</i>. 2008;26(15):2505-2511. doi: 10.1200/JCO.2007.11.9214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/18413642/pubmed\" target=\"_blank\" id=\"18413642\">18413642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21962016\"></a>Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. <i>J Heart Lung Transplant</i>. 2011;30(10):1078-1094. doi: 10.1016/j.healun.2011.08.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/21962016/pubmed\" target=\"_blank\" id=\"21962016\">21962016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor DO, Edwards LB, Aurora P, et al, &ldquo;Registry of the International Society for Heart and Lung Transplantation: Twenty-Fifth Official Adult Heart Transplant Report - 2008,&rdquo; <i>J Heart Lung Transplant</i>, 2008; 27(9):943-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/18765186/pubmed\" target=\"_blank\" id=\"18765186\">18765186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitehead B, James I, Helms P, et al, &ldquo;Intensive Care Management of Children Following Heart and Heart-Lung Transplantation,&rdquo; <i>Intensive Care Med</i>, 1990, 16(7):426-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-equine-atgam-drug-information/abstract-text/2269710/pubmed\" target=\"_blank\" id=\"2269710\">2269710</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9107 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708631\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F190616\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F190617\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F190635\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F190618\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F190629\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F190619\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25663816\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25663817\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F26343201\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F9885370\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F190599\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F190586\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F190601\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F190600\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474660\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F190640\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F190593\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F190604\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F190590\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298763\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218037\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F190606\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21098376\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F190597\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F190589\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F190603\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323348\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038667\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9107|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=antithymocyte-globulin-equine-atgam-patient-drug-information\" class=\"drug drug_patient\">Antithymocyte globulin (equine, Atgam): Patient drug information</a></li><li><a href=\"topic.htm?path=antithymocyte-globulin-equine-atgam-pediatric-drug-information\" class=\"drug drug_pediatric\">Antithymocyte globulin (equine, Atgam): Pediatric drug information</a></li></ul></div></div>","javascript":null}